tiprankstipranks
Trending News
More News >
Hikma Pharmaceuticals PLC (GB:HIK)
LSE:HIK
UK Market

Hikma Pharmaceuticals (HIK) Income Statement

Compare
90 Followers

Hikma Pharmaceuticals Income Statement

Last quarter (Q2 2025), Hikma Pharmaceuticals's total revenue was $1.66B, an increase of 16.19% from the same quarter last year. In Q2, Hikma Pharmaceuticals's net income was $238.00M. See Hikma Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 3.13B$ 2.88B$ 2.52B$ 2.55B$ 2.34B
Gross Profit
$ 1.42B$ 1.41B$ 1.26B$ 1.30B$ 1.21B
Operating Expenses
$ 803.00M$ 1.04B$ 976.00M$ 715.00M$ 621.00M
Depreciation and Amortization
$ 179.00M$ 172.00M$ 193.00M$ 144.00M$ 91.00M
EBITDA
$ 787.00M$ 791.00M$ 485.00M$ 744.00M$ 631.00M
Operating Income
$ 612.00M$ 367.00M$ 591.00M$ 634.00M$ 540.00M
Other Income/Expenses
$ -157.00M$ -86.00M$ -49.00M$ -38.00M$ 18.00M
Pretax Income
$ 455.00M$ 281.00M$ 233.00M$ 544.00M$ 558.00M
Net Income
$ 359.00M$ 190.00M$ 188.00M$ 421.00M$ 431.00M
Per Share Metrics
Basic EPS
$ 1.61$ 0.85$ 0.84$ 1.82$ 1.83
Diluted EPS
$ 1.61$ 0.85$ 0.84$ 1.81$ 1.81
Weighted Average Shares Outstanding
222.98M 222.37M 223.73M 231.00M 236.00M
Weighted Average Shares Outstanding (Diluted)
223.49M 222.37M 225.00M 233.00M 238.00M
Currency in USD

Hikma Pharmaceuticals Earnings and Revenue History